ADRA1A

Across TCGA pan-cancer cohorts, ADRA1A Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated ADRA1A data layer compared with 21 for mass-spec protein.

The strongest signal is observed in uterine carcinosarcoma (UCS), where higher ADRA1A Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ADRA1A expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

UCS, HNSC, and ESCA are the cancer types where ADRA1A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCS	DFS	Median	IV	0.192	0.776	<.001	48	view →
HNSC	OS	Median	III,IV	0.181	0.746	.001	18	view →
ESCA	DFS	Median	II,III,IV	0.179	0.525	.023	12	view →
SKCM	DFS	Median	All	0.265	0.766	<.001	12	view →
LUSC	DFS	Median	II,III,IV	0.307	0.616	.023	8	view →
READ	OS	Median	II,III,IV	0.219	0.679	.011	6	view →
UCEC	DFS	Median	All	0.959	0.827	.018	6	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

ADRA1A–UCS (DFS)

Open the UCS breakdown →